Ulcerative Colitis

Recent developments include: * MLN518: Based on data of MLN518 as a single agent in the relapsed treatment setting, the Company initiated a phase I/II, open-label, multi- center study of MLN518 in combination with standard induction chemotherapy in patients with newly diagnosed acute myelogenous leukemia.

Millennium also entered into a multi-year research agreement with the Cancer Therapy Evaluation Program, a branch of the National Cancer Institute and the National Institutes of Health, to explore the potential of MLN518 in a variety of tumor types.

The Company announced several additional pipeline advances in the fourth quarter 2005: * MLN3701: In December, the Company initiated a phase I trial in healthy volunteers with MLN3701, an oral CCR1 inhibitor, to test safety, tolerability, as well as pharmacokinetics/pharmacodynamics of the molecule.

* MLN8054: In November, the Company initiated a phase I trial in advanced malignancies with MLN8054, an oral, selective Aurora A kinase inhibitor discovered by Millennium.

This trial will examine the safety and activity of MLN8054 in a range of solid and hematological tumors.

* MLN0415: The Company also brought forward a new small molecule, MLN0415, an oral inhibitor of IKK beta, from its discovery organization to development candida...

Read more...